You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm intends to commercialize a probe that includes exhaled limonene and other biomarkers to enable clinicians to better identify disease stages.
The blood test will be available to specialty and primary care physicians across the US and Canada from LabCorp by early 2021.
The financing round was led by Asian private investment firm AT Capital and early-stage deep-tech venture capital fund Elev8.vc.
The company is initiating studies to detect responses to treatments for NASH, which may lead to an application for an FDA premarket approval.
Luminist Labs is developing diagnostic technology for liver disease, which DiscernDx will integrate into its precision medicine platform.
The companies will use ProSciento's Nash Pass patient registry and Nordic Bioscience's biomarker technology to validate the translational biomarkers.
The partners said that the first project will focus on the discovery of breath biomarkers for chronic liver diseases and liver-related cancers.
The partners plan to validate the accuracy, effectiveness, and clinical implications of Group K's MultiNostic liver function test, which is pending FDA clearance.
While results are preliminary, the test could potentially be used in lieu of a liver biopsy.
The researchers said a microbiome-based test could expand the number of individuals who are screened for the disease.
